First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children

Research output: Contribution to journalJournal articleResearchpeer-review

  • Selidji Todagbe Agnandji
  • Bertrand Lell
  • Solange Solmeheim Soulanoudjingar
  • José Francisco Fernandes
  • Béatrice Peggy Abossolo
  • Cornelia Conzelmann
  • Barbara Gaelle Nfono Ondo Methogo
  • Yannick Doucka
  • Arnaud Flamen
  • Benjamin Mordmüller
  • Saadou Issifou
  • Peter Gottfried Kremsner
  • Jahit Sacarlal
  • Pedro Aide
  • Miguel Lanaspa
  • John J Aponte
  • Arlindo Nhamuave
  • Diana Quelhas
  • Quique Bassat
  • Sofia Mandjate
  • Eusébio Macete
  • Pedro Alonso
  • Salim Abdulla
  • Nahya Salim
  • Omar Juma
  • Mwanajaa Shomari
  • Kafuruki Shubis
  • Francisca Machera
  • Ali Said Hamad
  • Rose Minja
  • Ali Mtoro
  • Alma Sykes
  • Saumu Ahmed
  • Alwisa Martin Urassa
  • Ali Mohammed Ali
  • Grace Mwangoka
  • Marcel Tanner
  • Halidou Tinto
  • Umberto D'Alessandro
  • Hermann Sorgho
  • Innocent Valea
  • Marc Christian Tahita
  • William Kaboré
  • Sayouba Ouédraogo
  • Yara Sandrine
  • Robert Tinga Guiguemdé
  • Jean Bosco Ouédraogo
  • Mary J Hamel
  • John Lusingu
  • Theander, Thor Grundtvig
  • RTS,S Clinical Trials Partnership
An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS,S/AS01 is being conducted in seven African countries.
Original languageEnglish
JournalNew England Journal of Medicine
Volume365
Issue number20
Pages (from-to)1863-75
Number of pages13
ISSN0028-4793
DOIs
Publication statusPublished - 2011

    Research areas

  • Africa, Age Factors, Double-Blind Method, Female, Follow-Up Studies, Humans, Incidence, Infant, Intention to Treat Analysis, Malaria Vaccines, Malaria, Falciparum, Male, Meningitis, Parasite Load, Plasmodium falciparum, Seizures, Treatment Outcome

ID: 35917734